ACE2 News and Research

RSS

"Immunological imprinting" could influence antibody response to COVID-19

Researchers in the United States and Spain have shown that prior exposure to seasonal coronaviruses may influence antibody responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19).

21 Oct 2020

Spike protein of SARS-CoV-2 virus identifies and binds neuropilin-1 on human cells to infect them

Helping to explain what makes SARS-CoV-2 so capable of infecting human cells, researchers in two independent studies discovered that the virus's spike protein recognizes and binds a protein on the human cell surface called neuropilin-1.

21 Oct 2020

Study shows SARS-CoV-2 uses a receptor to efficiently infect human cells

To efficiently infect human cells, SARS-CoV-2, the virus that causes COVID-19, is able to use a receptor called Neuropilin-1, which is very abundant in many human tissues including the respiratory tract, blood vessels and neurons.

21 Oct 2020

Researchers explore SARS-CoV-2 at single cell resolution in human airway epithelial cells

The cellular tropism of the SARS-CoV-2 virus affects several aspects of infection, such as the spread of the virus within and between hosts, tissue pathology, immune control mechanisms, and the response to treatment with promising antiviral drugs.

21 Oct 2020

Researchers explore effect of temperature on molecular structure of SARS-CoV-2 spike

Didac Martí et al., from the Polytechnic University of Catalonia, in a recent bioRxiv preprint research paper, explore the effect of the temperature on the molecular structure of the SARS-CoV-2 spike glycoprotein. The study specifically focuses on the spike glycoprotein's molecular structural integrity at different temperatures (within 25 ºC and 100 ºC) using atomistic computer simulations.

20 Oct 2020

Engineered decoy receptor could protect against coronaviruses

Researchers in the United States have shown that an engineered soluble decoy receptor tightly binds the spike protein of severe acute respiratory syndrome (SARS)-associated viruses. This could potentially provide protection against zoonotic betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

20 Oct 2020

Precision epidemiology could help explain variability in COVID-19 symptoms

Researchers from National Taiwan University have presented a multi-omics view of how mutations in angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) affect infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and progression of coronaviruses disease 2019 (COVID-19).

20 Oct 2020

Serious ongoing symptoms in COVID-19 survivors

Although predominantly a respiratory illness, emerging data suggests that multi-organ injury is common, particularly in moderate to severe infections. A new study published on the preprint server medRxiv* in October 2020 describes the illness's sequelae in the months after recovery.

20 Oct 2020

Androgen deprivation strategies could help mitigate SARS-CoV-2 infection

Since the beginning of the COVID-19 pandemic, researchers have noted that women are generally less severely affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This has led to the exploration into estrogen and androgens' role in the hyperinflammatory clinical phenotypes of COVID-19. A recent study published on the preprint server bioRxiv shows that drugs targeting androgens and TMPRSS2 inhibitors may potentially combat the pandemic.

20 Oct 2020

Molecular simulations reveal detailed structure and dynamics of SARS-CoV-2 spike protein

Recently, researchers reported a study in which they analyzed the structure and dynamics of the spike protein using multiple molecular dynamic simulations. Their study is published on the preprint server bioRxiv.

19 Oct 2020

Antigenic imprinting of sarbecovirus

A recent study published on the preprint server bioRxiv* in October 2020 shows that the design of a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) must consider the prior history of exposure to coronaviruses since these affect the antibody response to the virus.

19 Oct 2020

Study tackles the role of the renin-angiotensin system on COVID-19 pathophysiology

Vinicius Novaes Rocha, a researcher at the Federal University of Juiz de Fora in Brazil, provides an insight into the role of the renin-angiotensin on the pathophysiology of COVID-19, paving the way for developing new treatment methods in the journal Medical Hypotheses.

19 Oct 2020

Immunoglobulin M ACE2 autoantibodies associated with severe COVID-19

As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.

19 Oct 2020

CBD could reduce lung damage caused by COVID-19

One way CBD appears to reduce the "cytokine storm" that damages the lungs and kills many patients with COVID-19 is by enabling an increase in levels of a natural peptide called apelin, which is known to reduce inflammation and whose levels are dramatically reduced in the face of this storm.

19 Oct 2020

Obesity changes ACE2 and TMPRSS2 expression in mice: Implications for COVID-19

Researchers studying young obese mice found that expression of ACE2, a receptor in host cells that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is higher in the lungs and trachea of obese mice. The finding could partly explain why obesity is a high-risk factor for COVID-19.

18 Oct 2020

Rapid development of functionally diverse SARS-COV-2 mouse monoclonal antibodies

Now, a recent study published on the preprint server bioRxiv in October 2020 reports the development of a rapid process for generating high-affinity mouse mAbs, and their functional attributes.

16 Oct 2020

Sanofi Translate Bio MRT5500 COVID-19 vaccine shows promise in preclinical trials

The COVID-19 pandemic is threatening to come back in greater intensity during the winter and fall. Faced with this threat, vaccine development efforts are entering a phase of renewed focus, attempting to identify antigens capable of eliciting protective levels of neutralizing antibodies. A new study published on the preprint server bioRxiv* in October 2020 reports on a novel mRNA vaccine candidate's performance in two animal models.

16 Oct 2020

Human bivalent SARS-CoV-2 neutralizing antibodies more potent

A recent study published on the preprint server bioRxiv in October 2020 reports more effective viral neutralization by bivalent anti-spike antibodies. This could promote the development of better therapeutics and vaccines.

15 Oct 2020

The COVID-19 vaccine pipeline

Researchers from Mayo Clinic, United States of America, have reviewed the immunity developed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

14 Oct 2020

Exploring the effects of smoking tobacco on COVID-19 risk

A study conducted by researchers in China has shed light on how certain tobacco compounds might prevent cells from becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

14 Oct 2020